Intech Investment Management LLC Invests $126,000 in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)

Intech Investment Management LLC bought a new position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) during the third quarter, according to its most recent 13F filing with the SEC. The fund bought 10,855 shares of the specialty pharmaceutical company’s stock, valued at approximately $126,000.

Other large investors have also recently made changes to their positions in the company. nVerses Capital LLC bought a new stake in shares of KalVista Pharmaceuticals in the 2nd quarter worth about $25,000. China Universal Asset Management Co. Ltd. increased its holdings in shares of KalVista Pharmaceuticals by 67.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,286 shares of the specialty pharmaceutical company’s stock worth $96,000 after buying an additional 3,328 shares during the last quarter. SG Americas Securities LLC bought a new position in KalVista Pharmaceuticals during the 3rd quarter valued at about $153,000. Quest Partners LLC bought a new position in KalVista Pharmaceuticals during the 3rd quarter valued at about $175,000. Finally, Evoke Wealth LLC bought a new position in KalVista Pharmaceuticals during the 2nd quarter valued at about $181,000.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of KalVista Pharmaceuticals in a report on Monday, September 9th. Needham & Company LLC reiterated a “buy” rating and set a $28.00 price target on shares of KalVista Pharmaceuticals in a report on Thursday. Finally, HC Wainwright reiterated a “buy” rating and set a $20.00 price target on shares of KalVista Pharmaceuticals in a report on Friday.

Insider Activity at KalVista Pharmaceuticals

In related news, insider Paul K. Audhya sold 8,077 shares of the stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $9.26, for a total transaction of $74,793.02. Following the completion of the sale, the insider now owns 94,199 shares of the company’s stock, valued at $872,282.74. This represents a 7.90 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Benjamin L. Palleiko sold 7,352 shares of the company’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $12.19, for a total transaction of $89,620.88. Following the transaction, the chief executive officer now owns 250,800 shares in the company, valued at $3,057,252. The trade was a 2.85 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 32,016 shares of company stock valued at $319,344 over the last 90 days. Insiders own 10.50% of the company’s stock.

KalVista Pharmaceuticals Price Performance

KalVista Pharmaceuticals stock opened at $9.81 on Friday. The firm has a 50-day moving average of $10.90 and a two-hundred day moving average of $11.82. KalVista Pharmaceuticals, Inc. has a 1 year low of $7.39 and a 1 year high of $16.88. The stock has a market cap of $423.99 million, a price-to-earnings ratio of -2.70 and a beta of 0.85.

KalVista Pharmaceuticals (NASDAQ:KALV) last announced its quarterly earnings results on Thursday, September 5th. The specialty pharmaceutical company reported ($0.87) earnings per share for the quarter, topping the consensus estimate of ($0.91) by $0.04. Research analysts expect that KalVista Pharmaceuticals, Inc. will post -2.7 earnings per share for the current year.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).